| abstract |
The present invention relates to a pyrrolotriazine compound [4-[[1- (3-fluorophenyl) methyl] -1 H-indazol-5-ylamino] -5-methyl-pyrrolo [2,1-f] [ 1,2,4] triazine-6-yl] -carbamic acid, crystalline forms of (3S) -3-morpholinylmethyl esters, and pharmaceutical compositions comprising one or more crystalline forms, as well as in the treatment of proliferative diseases Methods for the use of crystalline forms of, and methods for obtaining such crystalline forms. [4-[[1- (3-fluorophenyl) methyl] -1H-indazol-5-ylamino] -5-methyl-pyrrolo [2,1-f] [1,2,4] triazine -6-yl] -carbamic acid, a compound of formula (I), including (3S) -3-morpholinylmethyl ester, is useful for inhibiting tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4, It may be useful as an antiproliferative agent for the treatment of cancer and other diseases. |